OKYO Pharma to Present at Ophthalmology Futures European Forum and iNovation Day at ESCRS 2026

OKYO Pharma highlights progress on its urcosimod program, including planned global Phase 3 enrollment and recent supportive FDA regulatory feedback.

Rhea-AI Summary

OKYO Pharma (OKYO) will present at the Ophthalmology Futures European Forum on September 10 and ESCRS iNovation Day on September 11, 2026, in London.

The company aims to engage clinicians, industry leaders, and investors as it advances urcosimod, its lead asset for neuropathic corneal pain (NCP), through its global Phase 3 pivotal NEPTUNE trial. OKYO reports recent positive feedback from a U.S. FDA Type D meeting, which it says validated the regulatory and clinical path forward for urcosimod, and notes an Annual Report filing reflecting a strengthened cash position. OKYO plans to initiate a global Phase 3 pivotal trial in the second half of this year, enrolling approximately 111 patients to evaluate a single-dose regimen of urcosimod for NCP.

Positive

• Planned global Phase 3 trial for urcosimod in NCP with approximately 111 patients in a single-dose regimen
• Positive FDA Type D feedback validating regulatory and clinical path forward for urcosimod
• Strengthened cash position reported in the recently filed Annual Report

Negative

• None.

Key Terms

neuropathic corneal pain, phase 3 pivotal trial

2 terms

neuropathic corneal pain medical

"treatment of neuropathic corneal pain (NCP) and anterior segment eye diseases"

Neuropathic corneal pain is chronic, often severe eye pain caused by damage or malfunction in the tiny nerves of the cornea, where the eye surface can feel burning, stinging, or like something is in it despite little visible damage. It matters to investors because it represents a persistent, hard-to-treat medical need that drives demand for new drugs, diagnostics, devices and regulatory approvals, similar to how fixing a frayed electrical wire stops false alarm signals.

phase 3 pivotal trial medical

"through its global Phase 3 pivotal trial for neuropathic corneal pain"

A phase 3 pivotal trial is the large, final clinical study that tests whether a new drug or medical treatment works and is safe enough for regulators to approve it for widespread use. Think of it as the full-scale dress rehearsal before a product launches: positive results can unlock regulatory approval and big commercial upside, while failures can halt a program and significantly affect investor value.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Company to engage with the global ophthalmology and investment community as it advances urcosimod through its global Phase 3 pivotal trial for neuropathic corneal pain

LONDON and NEW YORK, Sept. 09, 2026 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (Nasdaq: OKYO), a clinical-stage biopharmaceutical company developing investigational therapies for the treatment of neuropathic corneal pain (NCP) and anterior segment eye diseases, today announced that it will present at Ophthalmology Futures Forum and in the 5th Annual ESCRS iNovation Day.

Ophthalmology Futures European Forum on Thursday, September 10 in London is where clinical innovators, investors, and industry leaders convene to examine what's next in ophthalmology and where the next wave of value will be created.

ESCRS iNovation Day, taking place Friday, September 11, 2026 at ExCeL London, United Kingdom, held in conjunction with the 44th Congress of the ESCRS (European Society of Cataract and Refractive Surgeons), running September 11–15, 2026, is recognized as a cornerstone event for ophthalmic innovation in Europe, bringing together ophthalmologists, industry leaders, emerging companies and the financial community.

OKYO's continued conference participation reflects the clinical, industry, and investor communities central to advancing urcosimod, its lead asset, through its global Phase 3 pivotal NEPTUNE trial for NCP.

The Company's presence at the events follows recent positive feedback from its U.S. Food and Drug Administration (FDA) Type D meeting, which validated OKYO's regulatory and clinical path forward for urcosimod, as well as the filing of its Annual Report reflecting a strengthened cash position.

About OKYO Pharma

OKYO Pharma Limited (Nasdaq: OKYO) is a clinical-stage biopharmaceutical company developing innovative therapies for the treatment of neuropathic corneal pain (NCP) and anterior segment eye diseases, with ordinary shares listed for trading on the Nasdaq Capital Market. OKYO plans to initiate a global Phase 3 pivotal clinical trial in the second half of this year, enrolling approximately 111 patients to evaluate a single-dose regimen of urcosimod for the treatment of NCP.

For further information, please visit www.okyopharma.com.

For further inquiries:

OKYO Pharma Ltd
Paul Spencer
Business Development and Investor Relations
+44 (0) 207 495 2379
Email: info@okyopharma.com

FAQ

When and where will OKYO Pharma present to the ophthalmology community?

OKYO will present at the Ophthalmology Futures European Forum on Thursday, September 10, 2026, in London, and at the ESCRS iNovation Day on Friday, September 11, 2026, at ExCeL London, held in conjunction with the 44th Congress of the ESCRS running September 11–15, 2026.

What is known about the design of OKYO’s planned Phase 3 trial for urcosimod?

OKYO plans to initiate a global Phase 3 pivotal clinical trial in the second half of this year, enrolling approximately 111 patients to evaluate a single-dose regimen of urcosimod for the treatment of neuropathic corneal pain.

What indication is urcosimod being developed to treat?

Urcosimod is being developed for the treatment of neuropathic corneal pain (NCP) and other anterior segment eye diseases.